TY - JOUR
T1 - Rheumatologic immune checkpoint inhibitor-related adverse events
AU - Defoe, Melissa
AU - Bermas, Bonnie L.
N1 - Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/5/1
Y1 - 2023/5/1
N2 - Purpose of reviewImmune check point inhibitors (ICIs) are a unique class of cancer treatments that harness the body's innate antitumor response. Although these medications have transformed oncology care, they also lead to generalized immune activation that can result in toxicities across a spectrum of organ systems called immune-related adverse events. This article reviews the most common rheumatologic immune-related adverse events and their management.Recent findingsInflammatory arthritis, polymyalgia rheumatic, sicca symptoms, systemic sclerosis, myositis, and vasculitis have all been reported as ICI adverse events. Treatment includes nonsteroidal anti-inflammatory drugs, glucocorticoids, traditional DMARDs, and biologics.SummaryRheumatologists have an important role in the management of patients with rheumatologic immune-related adverse events. Working with our oncology colleagues, we can help manage rheumatologic immune-related adverse events while optimally preserving ICI's antitumor effects.
AB - Purpose of reviewImmune check point inhibitors (ICIs) are a unique class of cancer treatments that harness the body's innate antitumor response. Although these medications have transformed oncology care, they also lead to generalized immune activation that can result in toxicities across a spectrum of organ systems called immune-related adverse events. This article reviews the most common rheumatologic immune-related adverse events and their management.Recent findingsInflammatory arthritis, polymyalgia rheumatic, sicca symptoms, systemic sclerosis, myositis, and vasculitis have all been reported as ICI adverse events. Treatment includes nonsteroidal anti-inflammatory drugs, glucocorticoids, traditional DMARDs, and biologics.SummaryRheumatologists have an important role in the management of patients with rheumatologic immune-related adverse events. Working with our oncology colleagues, we can help manage rheumatologic immune-related adverse events while optimally preserving ICI's antitumor effects.
KW - immune checkpoint inhibitor
KW - immune-related adverse event
KW - inflammatory arthritis
KW - polymyalgia rheumatica
UR - http://www.scopus.com/inward/record.url?scp=85151417991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151417991&partnerID=8YFLogxK
U2 - 10.1097/BOR.0000000000000935
DO - 10.1097/BOR.0000000000000935
M3 - Review article
C2 - 36912045
AN - SCOPUS:85151417991
SN - 1040-8711
VL - 35
SP - 141
EP - 148
JO - Current Opinion in Rheumatology
JF - Current Opinion in Rheumatology
IS - 3
ER -